care. Over recent years, recommendations have focused on extending the duration of thromboprophylaxis after surgery to reduce VTEs that occur after discharge from hospital. Indeed, this study reports that almost half (49%) of VTEs in patients receiving cystectomy occur after hospital discharge, consistent with previous studies which include other urological procedures (3, 4) .
The time period examined in this study is of interest because it spans a time when important changes to thromboprophylaxis guideline recommendations were made. In 2012, the American College of Chest Physicians (ACCP) published landmark guidelines on venous thromboprophylaxis following non-orthopedic operations (5). This publication was the best recognized guide for VTE prophylaxis following abdominal and pelvic surgery (including urological surgery) prior to the recently published European Association of Urology (EAU) procedure-specific guidelines (6) . It is plausible that some of the improvements in VTE rates observed in this study are attributable to a change in practice patterns and the uptake of extended duration thromboprophylaxis following this publication.
A noteworthy strength of this study is that the results may indicate improvements in the quality of post-cystectomy care internationally. NSQIP has member institutions across the world, making the results more generalizable than most cystectomy series that are derived from a single or a few large academic centers. Because NSQIP does not contain granular data for all disease factors or treatments (prophylaxis) received, the study is unable to determine why VTE rates have decreased. Institutions enrolled in NSQIP are often larger and more academic, therefore it is possible hospital or system factors, rather than clinician practice, are contributing to improvements in VTE rates seen in this study. Factors such as peri-operative VTE prophylaxis care pathways and enhanced recovery after surgery (ERAS) protocols now used at many institutions, may reduce VTE rates by promoting earlier ambulation, less infections, and a more rapid resumption of regular activity.
As the authors acknowledge, NSQIP data has several important limitations when used to study VTE. Most importantly, information including the use of venous thromboprophylaxis, neoadjuvant chemotherapy, and oncological factors such as tumor grade and stage, are not included in NSQIP and therefore could not be adjusted for in this study. In addition, while it is highly encouraging to see VTE rates decrease, it would be more informative to have these data paired with bleeding rates at cystectomy in the same population. The benefits of thromboprophylaxis must always be balanced with the possible increased risk of major bleeding and transfusion. Future studies to assess VTE and bleeding rates over time are needed.
This study provides positive news for patients with bladder cancer who have amongst the highest burden of care of all urological patients and we commend the authors for their work. Despite these positive results, there remains much room for improvement in the prevention of VTE following urological surgery. Studies examining the timing, type, duration and effectiveness of medical and mechanical thromboprophylaxis in urology are still needed. Furthermore, tools to improve and facilitate risk stratification applicable to all urological procedures are required.
